达安基因
(002030)
| 流通市值：80.70亿 | | | 总市值：80.70亿 |
| 流通股本：14.03亿 | | | 总股本：14.03亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 327,825,993.97 | 149,439,274.94 | 757,661,908.2 | 503,506,935.73 |
| 营业总成本 | 434,890,916.9 | 205,156,295.51 | 1,054,914,863.88 | 720,643,863.72 |
| 其他经营收益 | | | | |
| 营业利润 | -135,292,257.47 | -99,292,949.03 | -753,353,917.63 | -165,399,620.81 |
| 利润总额 | -132,598,266.15 | -99,844,833.5 | -756,988,490.26 | -169,573,304.64 |
| 净利润 | -124,465,953.27 | -98,196,154.5 | -780,521,960.65 | -150,774,907.69 |
| 每股收益 | | | | |
| 其他综合收益 | -140,260.15 | -158,233.04 | 1,447,181.54 | -521,826.97 |
| 综合收益总额 | -124,606,213.42 | -98,354,387.54 | -779,074,779.11 | -151,296,734.66 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 2,726,383,442.8 | 2,799,737,143.82 | 2,843,590,585.47 | 2,874,172,411.62 |
| 非流动资产: | | | | |
| 非流动资产合计 | 5,555,202,988.13 | 5,534,741,831.98 | 5,666,915,803.01 | 6,219,511,774.13 |
| 资产总计 | 8,281,586,430.93 | 8,334,478,975.8 | 8,510,506,388.48 | 9,093,684,185.75 |
| 流动负债: | | | | |
| 流动负债合计 | 920,797,535.03 | 939,422,110.18 | 1,007,393,796.65 | 939,684,954.87 |
| 非流动负债: | | | | |
| 非流动负债合计 | 119,995,518.59 | 128,132,035.39 | 138,333,374.06 | 159,583,896.62 |
| 负债合计 | 1,040,793,053.62 | 1,067,554,145.57 | 1,145,727,170.71 | 1,099,268,851.49 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 7,017,656,920.57 | 7,039,665,873.18 | 7,137,861,022.77 | 7,740,704,825.2 |
| 股东权益合计 | 7,240,793,377.31 | 7,266,924,830.23 | 7,364,779,217.77 | 7,994,415,334.26 |
| 负债和股东权益合计 | 8,281,586,430.93 | 8,334,478,975.8 | 8,510,506,388.48 | 9,093,684,185.75 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 641,784,691.42 | 312,849,373.54 | 1,901,181,279.64 | 1,336,527,784.17 |
| 经营活动现金流出小计 | 616,100,955.5 | 358,483,021.58 | 1,581,692,026.28 | 1,255,009,882.62 |
| 经营活动产生的现金流量净额 | 25,683,735.92 | -45,633,648.04 | 319,489,253.36 | 81,517,901.55 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 1,203,277,113.71 | 309,622,899.04 | 1,858,778,023.28 | 1,260,437,399.11 |
| 投资活动现金流出小计 | 1,142,870,726.82 | 272,358,807.78 | 2,496,095,846.79 | 1,677,425,056.46 |
| 投资活动产生的现金流量净额 | 60,406,386.89 | 37,264,091.26 | -637,317,823.51 | -416,987,657.35 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 55,476,993.53 | 49,479,000 | 127,910,753.61 | 97,411,520.09 |
| 筹资活动现金流出小计 | 64,475,483.94 | 33,563,430.65 | 172,464,385.02 | 137,720,444.04 |
| 筹资活动产生的现金流量净额 | -8,998,490.41 | 15,915,569.35 | -44,553,631.41 | -40,308,923.95 |
| 汇率变动对现金及现金等价物的影响 | -1,410,104.33 | -720,604.91 | -1,331,249.4 | -887,822.91 |
| 现金及现金等价物净增加额 | 75,681,528.07 | 6,825,407.66 | -363,713,450.96 | -376,666,502.66 |
| 期末现金及现金等价物余额 | 579,339,955.37 | 510,483,834.96 | 503,658,427.3 | 490,705,375.6 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 75,681,528.07 | - | -363,713,450.96 | - |